| pubmed-article:2714274 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2714274 | lifeskim:mentions | umls-concept:C0558295 | lld:lifeskim |
| pubmed-article:2714274 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:2714274 | pubmed:dateCreated | 1989-6-22 | lld:pubmed |
| pubmed-article:2714274 | pubmed:abstractText | Among the DNA-intercalating drugs in the ellipticinium series, 9-hydroxy derivatives elicit the highest antitumoral properties. In water these drugs display a very low fluorescence quantum yield. Replacement of H2O by D2O partially restores the fluorescence of the ellipticinium chromophore. The possibility that such a proton-exchange mechanism could be involved in a base-recognizing process at the DNA level (and therefore be responsible for some base preference) was examined by direct fluorescence titration in deuterated buffer and DNA/drug fluorescence energy transfer. These experimental approaches provide mutually consistent results showing that the 9-hydroxylated drug recognizes specific DNA sites that are not recognized by the non-hydroxylated drug. When compared to 2-N-methyl ellipticinium, the 2-N-methyl 9-hydroxyellipticinium presents: (1) higher binding constants for each DNA studied; (2) a base dependence of the fluorescence properties of the bound form (fluorescence increment upon DNA binding varying over 5-11); (3) a base dependence of its DNA affinity constants (1.1-3.3 x 10(6) M-1) and of its site size (exclusion parameters varying over 3.0-4.4); (4) a base dependence of its energy transfer from DNA bases. Analysis of the binding data suggests that the 9-hydroxyl group of 2-N-methyl ellipticinium is responsible for a G.C base-pair preference, the preferred binding site being a doublet sequence of two adjacent G.C which could be flanked either by a additional G.C base pair or by an A.T base pair. | lld:pubmed |
| pubmed-article:2714274 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2714274 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2714274 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2714274 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2714274 | pubmed:issn | 0014-2956 | lld:pubmed |
| pubmed-article:2714274 | pubmed:author | pubmed-author:AuclairCC | lld:pubmed |
| pubmed-article:2714274 | pubmed:author | pubmed-author:DodinGG | lld:pubmed |
| pubmed-article:2714274 | pubmed:author | pubmed-author:PaolettiCC | lld:pubmed |
| pubmed-article:2714274 | pubmed:author | pubmed-author:SchwallerM... | lld:pubmed |
| pubmed-article:2714274 | pubmed:author | pubmed-author:AubardJJ | lld:pubmed |
| pubmed-article:2714274 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2714274 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:2714274 | pubmed:volume | 181 | lld:pubmed |
| pubmed-article:2714274 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2714274 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2714274 | pubmed:pagination | 129-34 | lld:pubmed |
| pubmed-article:2714274 | pubmed:dateRevised | 2007-7-23 | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:meshHeading | pubmed-meshheading:2714274-... | lld:pubmed |
| pubmed-article:2714274 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2714274 | pubmed:articleTitle | The G.C base-pair preference of 2-N-methyl 9-hydroxyellipticinium. | lld:pubmed |
| pubmed-article:2714274 | pubmed:affiliation | Unité de Biochimie-Enzymologie, UA 147 CNRS, U 140 INSERM, Villejuif, France. | lld:pubmed |
| pubmed-article:2714274 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2714274 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2714274 | lld:pubmed |
